Glycomimetic

Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Monday, November 22, 2021 - 1:40am

"AML is a highly aggressive hematological cancer, and the prognosis of patients with relapsed or refractory disease is extremely poor.

Key Points: 
  • "AML is a highly aggressive hematological cancer, and the prognosis of patients with relapsed or refractory disease is extremely poor.
  • This combined treatment approach could have a meaningful impact on the lives of patients living with relapsed or refractory AML."
  • The Phase 3 trial with APL-106 is part of the overall development program for Apollomics in China that also includes an ongoing Phase 1 pharmacokinetics (PK) and tolerability study.
  • The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to uproleselan for the treatment of adults with relapsed or refractory acute myeloid leukemia.

Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Monday, November 22, 2021 - 12:10pm

AML is a highly aggressive hematological cancer, and the prognosis of patients with relapsed or refractory disease is extremely poor.

Key Points: 
  • AML is a highly aggressive hematological cancer, and the prognosis of patients with relapsed or refractory disease is extremely poor.
  • This combined treatment approach could have a meaningful impact on the lives of patients living with relapsed or refractory AML.
  • The Phase 3 trial with APL-106 is part of the overall development program for Apollomics in China that also includes an ongoing Phase 1 pharmacokinetics (PK) and tolerability study.
  • The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to uproleselan for the treatment of adults with relapsed or refractory acute myeloid leukemia.

Ichnos Sciences Welcomes Eric Feldman, M.D., as New Chief Medical Officer

Monday, November 8, 2021 - 12:30pm

NEW YORK, Nov. 8, 2021 /PRNewswire/ --Ichnos Sciences Inc., a global biotechnology company developing innovative biologic treatments in oncology and autoimmune diseases, today announced the appointment of Eric J. Feldman, M.D., to the position of Chief Medical Officer (CMO), effective immediately.

Key Points: 
  • NEW YORK, Nov. 8, 2021 /PRNewswire/ --Ichnos Sciences Inc., a global biotechnology company developing innovative biologic treatments in oncology and autoimmune diseases, today announced the appointment of Eric J. Feldman, M.D., to the position of Chief Medical Officer (CMO), effective immediately.
  • Dr. Feldman, who reports to President and Chief Executive Officer Cyril Konto, M.D., will be responsible for all pipeline development activities, including Clinical Development, Clinical Operations, Regulatory Sciences, Pharmacokinetics and Translational Sciences, Biometrics and Drug Safety.
  • Previously, Dr. Feldman served as Senior Vice President, Chief Medical Officer, at GlycoMimetics, leading the Phase 3 registration study of uproleselan in acute myeloid leukemia, as well as other early-stage assets.
  • Dr. Feldman received a medical degree at New York Medical College, and he holds a B.A.

Ichnos Sciences Welcomes Eric Feldman, M.D., as New Chief Medical Officer

Monday, November 8, 2021 - 12:30pm

NEW YORK, Nov. 8, 2021 /PRNewswire/ --Ichnos Sciences Inc., a global biotechnology company developing innovative biologic treatments in oncology and autoimmune diseases, today announced the appointment of Eric J. Feldman, M.D., to the position of Chief Medical Officer (CMO), effective immediately.

Key Points: 
  • NEW YORK, Nov. 8, 2021 /PRNewswire/ --Ichnos Sciences Inc., a global biotechnology company developing innovative biologic treatments in oncology and autoimmune diseases, today announced the appointment of Eric J. Feldman, M.D., to the position of Chief Medical Officer (CMO), effective immediately.
  • Dr. Feldman, who reports to President and Chief Executive Officer Cyril Konto, M.D., will be responsible for all pipeline development activities, including Clinical Development, Clinical Operations, Regulatory Sciences, Pharmacokinetics and Translational Sciences, Biometrics and Drug Safety.
  • Previously, Dr. Feldman served as Senior Vice President, Chief Medical Officer, at GlycoMimetics, leading the Phase 3 registration study of uproleselan in acute myeloid leukemia, as well as other early-stage assets.
  • Dr. Feldman received a medical degree at New York Medical College, and he holds a B.A.

Efficacy and Safety Data for GlycoMimetics’ Lead Investigational Drug Uproleselan Published in BLOOD

Thursday, September 23, 2021 - 9:00pm

Efficacy and safety data from a Phase 1/2 clinical study of uproleselan, GlycoMimetics lead investigational drug, were published online September 16, 2021 in the journal BLOOD.

Key Points: 
  • Efficacy and safety data from a Phase 1/2 clinical study of uproleselan, GlycoMimetics lead investigational drug, were published online September 16, 2021 in the journal BLOOD.
  • The results of this Phase 1/2 study demonstrate the safety and tolerability of uproleselan in combination with an intensive salvage chemotherapeutic regimen.
  • Discovered and developed by GlycoMimetics, uproleselan is an investigational, first-in-class, targeted inhibitor of E-selectin.
  • In a Phase 1/2 clinical trial, uproleselan was evaluated in both newly diagnosed elderly and relapsed/refractory patients with AML.

ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors

Wednesday, September 22, 2021 - 9:01pm

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Helen M. Thackray, MD, FAAP to its Board of Directors.

Key Points: 
  • ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Helen M. Thackray, MD, FAAP to its Board of Directors.
  • "Helen joins ImmunoGen's Board of Directors at an exciting time, as we advance multiple programs in the clinic and transform ImmunoGen into a fully integrated oncology company with the potential to launch two innovative ADCs next year," said Stephen McCluski, ImmunoGen's Chairman of the Board of Directors.
  • Dr. Thackray has over 25 years of biopharmaceutical, clinical research, and bench research experience.
  • Dr. Thackray stated, "ImmunoGen has established a leadership position in ADCs and built a strong pipeline targeting solid tumors and hematologic malignancies.